特利加压素对肝切除术后门静脉压力及临床结局影响的前瞻性初步研究
本研究前瞻性纳入110例肝切除术后患者,对门静脉压力>12 mmHg者给予特利加压素,其中71%患者门静脉压力下降。应答者术后腹腔引流量和肝衰竭发生率低于非应答者,急性肾损伤、并发症及副作用无差异。
要点
- 肝切除术后门静脉压力>12 mmHg者可用特利加压素降低门静脉压力。
- 特利加压素应答者术后腹腔引流量和肝衰竭发生率更低。
- 特利加压素未增加急性肾损伤、并发症及副作用。
核心结论
- 特利加压素可降低肝切除术后门静脉压力,并可能减少肝切除术后肝衰竭发生率和术后腹腔引流量。
研究设计与样本
- 前瞻性初步研究,纳入110例肝切除术后患者,其中65例门静脉压力>12 mmHg者符合特利加压素给药条件。
主要发现
- 46例(71%)患者门静脉压力下降,平均门静脉压力从15.8 ± 2.6 mmHg降至14.3 ± 2.9 mmHg(P < .001)。
- 应答者术后前3天腹腔引流量中位数[四分位距]低于非应答者(350 mL [228-573] vs 730 mL [330-980];P = .004)。
- 应答者肝切除术后肝衰竭发生率低于非应答者(26% vs 53%,P = .04)。
- 急性肾损伤、手术并发症和特利加压素副作用在两组间无差异。
关键数值与推荐
- 门静脉压力>12 mmHg且特利加压素后压力下降者为应答者,接受特利加压素2 mg/天持续输注4天。
- 应答者肝切除术后肝衰竭发生率为26%,非应答者为53%(P = .04)。
临床怎么用
- 肝切除术后可监测门静脉压力,对压力>12 mmHg者考虑使用特利加压素以降低门静脉压力。
- 特利加压素可能减少肝切除术后肝衰竭和腹腔引流量,但需进一步研究确认。
局限性
- 本研究为初步研究,样本量有限,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Portal hypertension after hepatectomy is associated with impaired postoperative recovery. Terlipressin decreased portal vein pressure in patients with variceal bleeding and improved patient survival, but the role of postoperative terlipressin treatment for patients who underwent liver resection is not clear. METHODS: We determined the effect of terlipressin on portal vein pressure in patients with portal vein pressure >12 mmHg after hepatectomy. If portal vein pressure was decreased (ie, Responders), a continuous infusion of terlipressin at 2 mg/day for 4 days was given. The incidence of posthepatectomy liver failure, abdominal drainage, acute kidney injury, operative complications, and side-effects of terlipressin in the Responders were compared with those whose portal vein pressure did not decrease (ie, non-Responders) and patients whose portal vein pressure was ≤12 mmHg after hepatectomy (low portal vein pressure group). RESULTS: We recruited 110 patients, 65 of whom were eligible for terlipressin administration. Portal vein pressure decreased in 46 patients (71%) with the mean portal vein pressure decreasing from 15.8 ± 2.6 mmHg to 14.3 ± 2.9 mmHg (P < .001). The median [interquartile range] postoperative abdominal drainage for the first 3 postoperative days was less in the Responders than in the non-Responders (350 mL [228-573] vs 730 mL [330-980]; P = .004). Incidence of posthepatectomy liver failure in the Responders was less than the non-Responders (26% vs 53%, P = .04). Acute kidney injury, operative complications, and side-effects of terlipressin were not different between groups. CONCLUSION: Terlipressin decreased posthepatectomy portal vein pressure and may decrease the incidence of posthepatectomy liver failure and postoperative abdominal drainage (NCT03352349).
引用
- Li XL, Zhu XD, Xiao N, et al. A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study. Surgery. 2020. PMID: 32113581. doi:10.1016/j.surg.2020.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。